

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



GREATVIEW ASEPTIC PACKAGING COMPANY LIMITED
紛美包裝有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock code: 00468)

(1) RESUMPTION GUIDANCE
(2) QUARTERLY UPDATE ON THE STATUS OF RESUMPTION
AND
(3) CONTINUED SUSPENSION OF TRADING

This announcement is made by Greatview Aseptic Packaging Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to (i) the announcement made by the Company dated 19 February 2025 in relation to the suspension of trading in the shares of the Company; (ii) the announcements made by the Company dated 31 December 2024, 20 January 2025, 28 February 2025 and 17 April 2025 in relation to, among other things, an independent investigation on (a) the basis for consolidation of the Group’s international business following the restructuring; (b) the accuracy of the information and the size tests calculation concerning the transactions referred in the Company’s announcement dated 29 January 2024 (the “**Restructuring**”); and (c) other matters concerning the alleged incomplete or inaccurate disclosure of financial information, including but not limited to unauthorised use of financial funds, inadequate disclosure of related-party transactions and the presence of clandestine contracts under the Restructuring (collectively, the “**Matters**”); and (iii) the announcements made by the Company dated 25 March 2025 and 30 April 2025 (the “**April 30 Announcement**”) in relation to, among other things, the delay in publication of the Company’s annual results for the year ended 31 December 2024 (the “**Delay in Publication of 2024 Results**”).

(1) RESUMPTION GUIDANCE

The Company received a letter from the Stock Exchange dated 12 May 2025 which sets out the following resumption guidance (the “**Resumption Guidance**”) for the resumption of trading in the shares of the Company:

- (i) restore the minimum public float required under Rule 8.08(1)(a) of the Listing Rules;
- (ii) publish all outstanding financial results required under the Listing Rules and address any audit modifications;
- (iii) conduct an independent forensic investigation into the Matters (the “**Investigation**”), assess the impact on the Company’s business operation and financial position, announce the findings of the investigation and take appropriate remedial actions;
- (iv) demonstrate that there is no reasonable regulatory concern about the integrity, competence and/or character of the Group’s management and/or any person with substantial influence over the Company’s management and operations, which may pose a risk to investors and damage market confidence;
- (v) conduct an independent internal control review and demonstrate that the Company has in place adequate internal controls and procedures to comply with the Listing Rules;
- (vi) demonstrate the Company’s compliance with Rule 13.24 of the Listing Rules; and
- (vii) inform the market of all material information for the Company’s shareholders and investors to appraise its position.

The Company must meet all Resumption Guidance, remedy the issues causing its trading suspension and fully comply with the Listing Rules to the Stock Exchange’s satisfaction before trading in its securities is allowed to resume. The Stock Exchange has also indicated that it may modify or supplement the Resumption Guidance if the Company’s situation changes.

Under Rule 6.01A(1) of the Listing Rules, the Stock Exchange may cancel the listing of any securities that have been suspended from trading for a continuous period of 18 months. In the case of the Company, the 18-month period expires on 18 August 2026. If the Company fails to remedy the issues causing its trading suspension, fulfill the Resumption Guidance and fully comply with the Listing Rules to the Stock Exchange’s satisfaction and resume trading in its shares by 18 August 2026, the Listing Division of the Stock Exchange will recommend the Listing Committee of the Stock Exchange to proceed with the cancellation of the Company’s listing. Under Rules 6.01 and 6.10 of the Listing Rules, the Stock Exchange also has the right to impose a shorter specific remedial period, where appropriate.

The Company must also comply with the Listing Rules and all applicable laws and regulations in Hong Kong and the Cayman Islands, being its place of incorporation, before resumption.

The Company is taking appropriate steps to resolve the issues causing its trading suspension and to fully comply with the Listing Rules to the Stock Exchange's satisfaction.

Further announcement(s) will be made by the Company as and when appropriate and in accordance with the requirements of the Listing Rules to keep its shareholders and potential investors informed of the latest progress in complying with the Resumption Guidance. The Company shall announce further quarterly update every three (3) months from the date of suspension of trading until resumption or cancellation of listing (whichever is earlier).

(2) QUARTERLY UPDATE ON THE STATUS OF RESUMPTION

The Board wishes to update the Shareholders of, and potential investors in, the Company regarding the latest developments in relation to the Resumption Guidance.

Transition steps and continuing business operations of the Group

Reference is made to the announcement dated 18 February 2025 made by Jingfeng Holding Limited in relation to the close of the voluntary conditional general cash offer for all the issued Shares in the Company (other than those already held or agreed to be acquired by the Offeror and the Offeror concert parties) (the “Offer”).

Since the close of the Offer and change in Company's management, the Board has focused its efforts on ensuring a seamless transition in the handover of the Group. This involves safeguarding books and records of the Group, implementing changes in the management of the subsidiaries of the Company to enhance overall governance, and engaging with key stakeholders and customers to reassure them about business continuity and minimize any potential impact on the Group's operations (the “Transition”). As of the date of this announcement, the Group continues to carry on its ordinary course of business, and the Transition is ongoing. The Board will make further announcement(s) in relation to the status of the Transition as and when appropriate in accordance with the Listing Rules.

Status of the Investigation

The Board has been informed by the investigation committee that, following changes in its composition, the committee has been collaborating with Grant Thornton Advisory Services Limited, the independent forensic accountant, to review and consider preliminary findings of the Investigation. Efforts are underway to collect outstanding information and address outstanding issues to expedite completion of the Investigation.

Status of the preparation of the outstanding financial results

As part of the Transition efforts and considering the Delay in Publication of the 2024 Results, the Board has engaged in active discussions with the auditors of the Company and has also been working closely with them in order to address any outstanding audit tasks and to complete the audit of the 2024 annual results as soon as possible.

(3) CONTINUED SUSPENSION OF TRADING

Trading in the shares of the Company has been suspended with effect from 9:00 a.m. on 19 February 2025 and will remain suspended until further notice.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Greatview Aseptic Packaging Company Limited
WANG Ziting
Chairman and Executive Director

Beijing, the People's Republic of China, 16 May 2025

As at the date of this announcement, the Board comprises four executive directors, namely, Mr. YUAN Xunjun, Mr. BI Hua, Jeff, Ms. QI Zhaohui and Ms. WANG Ziting; four non-executive directors, namely, Ms. WEI Wei, Mr. CHOI Sum Shing Samson, Mr. YUEN Kai Yiu Kelvin and Mr. CHEN Min; and four independent non-executive directors, namely Ms. KOU Chung Yin Mariana, Mr. TANG Poon Tung Denny, Mr. CHOI Wai Hong Clifford and Mr. CHEN Qi